NYSE · CIK 0000876343
LCTX Lineage Cell Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jul 2, 2026. Close $0.95 on Oct 12, 2026, +6% from the 52-week low and -52% from the high.
In brief
Lineage Cell Therapeutics, Inc. (LCTX) has 37 SEC Form 4 filings on file from 11 insiders, the latest filed on Jul 2, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
10 open-market trades have been scored at LCTX. The newest: Brian M Culley (President and CEO) bought $24k of stock on Mar 12, 2026, filed Mar 12, 2026, scored 32 (weak). The largest of the 10 shown: Broadwood Partners, L.p. (director and 10% owner) bought $7.0M on Feb 6, 2024, scored 65 (notable). 4 insiders bought within 14 days of each other around Nov 26, 2024.
2 Form 144 notices of planned sales are on file, the latest filed Sep 24, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Lineage Cell Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 32Weak | Brian M Culley President and CEO buy | $24k 15,000 shares | +6% | +305% from low-19% from high | |
| 43Moderate | Broadwood Partners, L.p. director, owner buy | $6.0M 7,894,737 shares | +19% | - | |
| 47Moderate | Jill Ann Howe Chief Financial Officer buy | $8,850 15,000 shares | +143% | - | |
| 40Moderate | George A. Samuel III General Counsel buy | $9,000 15,000 shares | +209% | - | |
| 33Weak | Michael H. Mulroy director buy | $23k 40,000 shares | +15% | - | |
| 46Moderate | Brian M Culley President and CEO buy | $24k 40,000 shares | +26% | - | |
| 36Weak | Brian M Culley President and CEO buy | $11k 10,000 shares | +7% | +22% from low-31% from high | |
| 47Moderate | Don M Bailey director buy | $100k 96,155 shares | +153% | +26% from low-29% from high | |
| 65Notable | Broadwood Partners, L.p. director, owner buy | $7.0M 6,730,770 shares | +19% | +29% from low-27% from high | |
| 27Weak | Anula Jayasuriya director buy | $11k 10,000 shares | - | +20% from low-29% from high |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Sep 24, 2025 | DON M BAILEY Director | 60,000 0.03% of outstanding | $96k | Sep 24, 2025 | $97k |
| Sep 10, 2025 | DON M BAILEY Director | 80,000 0.03% of outstanding | $97k | Sep 10, 2025 | none |
Transactions
The newest 50 of 53 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Neal C Bradsher director, owner | AGrant or award OPTION TO PURCHASE COMMON SHARESderivative | +125,000 | $0.00 | $0 | 125,000 | Jul 2, 2026 |
| Jul 1, 2026 | Michael H. Mulroy director | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Jul 2, 2026 |
| Jul 1, 2026 | Angus C. Russell director | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Jul 2, 2026 |
| Jul 1, 2026 | Deborah J Andrews director | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Jul 2, 2026 |
| Jul 1, 2026 | Anula Jayasuriya director | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Jul 2, 2026 |
| Jul 1, 2026 | Dipti Amin director | AGrant or award Stock Option (Right to Buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Jul 2, 2026 |
| Mar 12, 2026 | Brian M Culley President and CEO | POpen-market purchase Common Shares | +15,000 | $1.63 | $24k | 255,516 | Mar 12, 2026 |
| Mar 5, 2026 | Brian M Culley President and CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +3,250,000 | $0.00 | $0 | 3,250,000 | Mar 6, 2026 |
| Mar 5, 2026 | Jill Ann Howe Chief Financial Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +1,050,000 | $0.00 | $0 | 1,050,000 | Mar 6, 2026 |
| Mar 5, 2026 | George A. Samuel III General Counsel and Secretary | AGrant or award Employee Stock Option (Right to Buy)derivative | +900,000 | $0.00 | $0 | 900,000 | Mar 6, 2026 |
| Feb 11, 2026 | Brian M Culley President and CEO | MOption exercise Common Shares | +31,250 | - | - | 253,385 | Feb 13, 2026 |
| Feb 11, 2026 | George A. Samuel III General Counsel and Secretary | MOption exercise Common Shares | +6,075 | - | - | 33,565 | Feb 13, 2026 |
| Feb 11, 2026 | Brian M Culley President and CEO | FTax withholding Common Shares | -12,869 | $1.80 | $23k | 240,516 | Feb 13, 2026 |
| Feb 11, 2026 | George A. Samuel III General Counsel and Secretary | FTax withholding Common Shares | -2,502 | $1.80 | $4,504 | 31,063 | Feb 13, 2026 |
| Feb 11, 2026 | George A. Samuel III General Counsel and Secretary | MOption exercise Restricted Stock Unitsderivative | -6,075 | $0.00 | $0 | 0 | Feb 13, 2026 |
| Feb 11, 2026 | Brian M Culley President and CEO | MOption exercise Restricted Stock Unitsderivative | -31,250 | $0.00 | $0 | 0 | Feb 13, 2026 |
| Dec 19, 2025 | Brian M Culley President and CEO | AGrant or award Common Shares | +8,925 | - | - | 222,469 | Dec 19, 2025 |
| Dec 19, 2025 | George A. Samuel III General Counsel and Secretary | AGrant or award Common Shares | +1,735 | - | - | 27,555 | Dec 19, 2025 |
| Dec 19, 2025 | Brian M Culley President and CEO | FTax withholding Common Shares | -334 | $1.68 | $561 | 222,135 | Dec 19, 2025 |
| Dec 19, 2025 | George A. Samuel III General Counsel and Secretary | FTax withholding Common Shares | -65 | $1.68 | $109 | 27,490 | Dec 19, 2025 |
| Jul 1, 2025 | Neal C Bradsher director, owner | AGrant or award OPTION TO PURCHASE COMMON SHARESderivative | +75,000 | $0.00 | $0 | 75,000 | Jul 3, 2025 |
| Jul 1, 2025 | Deborah J Andrews director | AGrant or award Stock Option (Right to Buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Jul 2, 2025 |
| Jul 1, 2025 | Dipti Amin director | AGrant or award Stock Option (Right to Buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Jul 2, 2025 |
| Jul 1, 2025 | Anula Jayasuriya director | AGrant or award Stock Option (Right to Buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Jul 2, 2025 |
| Jul 1, 2025 | Michael H. Mulroy director | AGrant or award Stock Option (Right to Buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Jul 2, 2025 |
| Jul 1, 2025 | Angus C. Russell director | AGrant or award Stock Option (Right to Buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Jul 2, 2025 |
| Mar 10, 2025 | Brian M Culley President and CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +2,300,000 | $0.00 | $0 | 2,300,000 | Mar 12, 2025 |
| Mar 10, 2025 | Jill Ann Howe Chief Financial Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +750,000 | $0.00 | $0 | 750,000 | Mar 12, 2025 |
| Feb 11, 2025 | Brian M Culley President and CEO | MOption exercise Common Shares | +31,249 | - | - | 226,091 | Feb 12, 2025 |
| Feb 11, 2025 | Brian M Culley President and CEO | FTax withholding Common Shares | -12,547 | $0.65 | $8,156 | 213,544 | Feb 12, 2025 |
| Feb 11, 2025 | Brian M Culley President and CEO | MOption exercise Restricted Stock Unitsderivative | -31,249 | $0.00 | $0 | 31,250 | Feb 12, 2025 |
| Jan 27, 2025 | Broadwood Partners, L.p. director, owner | POpen-market purchase Common Shares | +7,894,737 | $0.76 | $6.0M | 49,560,992 | Jan 28, 2025 |
| Jan 27, 2025 | Broadwood Partners, L.p. director, owner | POpen-market purchase Common Sharesindirect: See Footnote | +0 | $0.00 | $0 | 49,560,992 | Jan 28, 2025 |
| Jan 27, 2025 | Broadwood Partners, L.p. director, owner | POpen-market purchase Common Warrantderivative | +7,894,737 | $0.00 | $0 | 7,894,737 | Jan 28, 2025 |
| Jan 27, 2025 | Broadwood Partners, L.p. director, owner | POpen-market purchase Common Warrantderivativeindirect: See Footnote | +0 | $0.00 | $0 | 7,894,737 | Jan 28, 2025 |
| Nov 26, 2024 | Jill Ann Howe Chief Financial Officer | POpen-market purchase Common Shares | +15,000 | $0.59 | $8,850 | 25,500 | Nov 26, 2024 |
| Nov 26, 2024 | George A. Samuel III General Counsel | POpen-market purchase Common Shares | +15,000 | $0.60 | $9,000 | 22,184 | Nov 26, 2024 |
| Nov 22, 2024 | Michael H. Mulroy director | POpen-market purchase Common Shares | +40,000 | $0.57 | $23k | 298,555 | Nov 25, 2024 |
| Nov 21, 2024 | Brian M Culley President and CEO | POpen-market purchase Common Shares | +40,000 | $0.60 | $24k | 194,842 | Nov 22, 2024 |
| May 24, 2024 | Brian M Culley President and CEO | POpen-market purchase Common Shares | +10,000 | $1.05 | $11k | 154,842 | May 28, 2024 |
| Mar 7, 2024 | Brian M Culley President and CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +1,900,000 | $0.00 | $0 | 1,900,000 | Mar 8, 2024 |
| Mar 7, 2024 | Jill Ann Howe Chief Financial Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +650,000 | $0.00 | $0 | 650,000 | Mar 8, 2024 |
| Mar 7, 2024 | George A. Samuel III General Counsel/Secretary | AGrant or award Employee Stock Option (Right to Buy)derivative | +650,000 | $0.00 | $0 | 650,000 | Mar 8, 2024 |
| Feb 11, 2024 | Brian M Culley President and CEO | MOption exercise Common Shares, no par value | +31,249 | - | - | 157,648 | Feb 12, 2024 |
| Feb 11, 2024 | George A. Samuel III General Counsel/Secretary | MOption exercise Common Shares, no par value | +6,076 | - | - | 9,674 | Feb 12, 2024 |
| Feb 11, 2024 | Brian M Culley President and CEO | FTax withholding Common Shares, no par value | -12,806 | $1.08 | $14k | 144,842 | Feb 12, 2024 |
| Feb 11, 2024 | George A. Samuel III General Counsel/Secretary | FTax withholding Common Shares, no par value | -2,490 | $1.08 | $2,689 | 7,184 | Feb 12, 2024 |
| Feb 11, 2024 | Brian M Culley President and CEO | MOption exercise Restricted Stock Unitsderivative | -31,249 | $0.00 | $0 | 62,499 | Feb 12, 2024 |
| Feb 11, 2024 | George A. Samuel III General Counsel/Secretary | MOption exercise Restricted Stock Unitsderivative | -6,076 | $0.00 | $0 | 12,151 | Feb 12, 2024 |
| Feb 8, 2024 | Don M Bailey director | POpen-market purchase Common Shares, no par valueindirect: By The Bailey Family Trust | +96,155 | $1.04 | $100k | 158,801 | Feb 8, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Deborah J Andrewscfo, officer, director, ceo
- Dipti Amindirector
- Don M Baileydirector
- Neal C Bradsherowner, director
- Broadwood Partners, L.p.owner, director
- Brian M CulleyPresident and CEO
- Jill Ann HoweChief Financial Officer
- Anula Jayasuriyadirector
- Michael H. Mulroydirector
- Angus C. Russelldirector
- George A. Samuel IIIGeneral Counsel/Secretary
Questions about LCTX
Answered from the filings on this page, as of the latest one.
Are insiders buying LCTX?
No. In the last 90 days no insider at Lineage Cell Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade LCTX on the open market?
Brian M Culley (President and CEO) bought $24k of LCTX on Mar 12, 2026 and filed the Form 4 on Mar 12, 2026. InsiderTell scored 32 (weak).
How many insiders file Form 4 at Lineage Cell Therapeutics, Inc.?
11 people have filed a Form 4 at Lineage Cell Therapeutics, Inc., among them Deborah J Andrews (CFO, director and CEO), Dipti Amin (director), Don M Bailey (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.